AISAP's AI Platform Cuts Cardiac Diagnosis Time and Boosts Patient Care
AISAP's AI-driven cardiac ultrasound technology, recently featured in a WHO report, is transforming bedside diagnostics at Sheba Medical Center, with findings prompting critical medication changes and interventions.
Key Facts
- AISAP's AI platform reduced cardiac diagnosis time to under five minutes, enhancing patient care efficiency.
- 29% of patients had new diagnoses, indicating significant clinical impact and market demand for AI solutions.
- 100% sensitivity in detecting left ventricular dysfunction shows AISAP's competitive edge in diagnostic accuracy.
- Over 30% of cases led to treatment changes, highlighting financial implications through potential cost savings.
- WHO recognition positions AISAP favorably, indicating strategic market validation and growth opportunities.
Summary
Summary
AISAP, an AI platform for point of care ultrasound, partnered with Sheba Medical Center to enhance cardiac diagnostics. The challenge was to reduce the time for bedside cardiac diagnosis, which was traditionally lengthy. The solution involved deploying AI-enhanced ultrasound, resulting in diagnoses within five minutes and significant treatment changes for over 30% of patients.
Background
Sheba Medical Center, located in Israel, is recognized as one of the world's leading hospitals. Prior to the deployment of AISAP's technology, the process for cardiac diagnosis in the internal medicine and emergency departments was time-consuming, often requiring specialized training and lengthy procedures.
Challenge
The primary issue was the prolonged time required for cardiac diagnosis at the bedside, which limited the ability of clinicians to make timely treatment decisions. The hospital sought a solution that would enable faster, accurate diagnostics without the need for extensive sonography training.
Solution
AISAP implemented its AI-enhanced, AI-guided cardiac ultrasound system within Sheba's internal medicine and emergency departments. This system allowed physicians without formal sonography training to perform cardiac evaluations. Between July 2022 and December 2023, 660 patients were evaluated using this technology, which enabled scans to be completed in under five minutes.
Results
The deployment of AISAP's technology led to the identification of clinically relevant cardiac findings in 193 patients (29%), including 147 previously undocumented diagnoses (22%). Additionally, it prompted medication changes in 49 patients (7%) and interventional procedures in 9 patients (1.4%). In a subset of 117 patients validated against formal echocardiography, the AI-enhanced ultrasound demonstrated 100% sensitivity and 96.9% specificity for detecting significant left ventricular dysfunction.
Key Insights
The case illustrates the potential of AI to streamline diagnostic processes in healthcare, enabling rapid decision-making and improving patient outcomes. The deployment of AI-guided tools can empower clinicians with limited training to deliver specialist-level care efficiently.
Customer Testimonial
"Being recognized by the World Health Organization validates what we've seen firsthand at Sheba: AI-guided POCUS can bring specialist-level cardiac diagnostics to any clinician, at any bedside, in minutes rather than hours. This is what validated AI can deliver, rapid, expert-level care directly to patients, across hospital departments," said Robert Klempfner, Chief Medical Officer & Co-Founder at AISAP.
Entities Mentioned
Companies
Products
Technologies
People
Organizations
Key Concepts
Definitions
- AI-enhanced FoCUS
- AI-enhanced Focused Cardiac Ultrasound (FoCUS) refers to the use of artificial intelligence to assist in performing cardiac ultrasound examinations.
- POCUS
- Point of Care Ultrasound (POCUS) is a portable ultrasound technology used for immediate diagnostic purposes at the patient's bedside.
- FDA clearance
- FDA clearance is the approval granted by the U.S. Food and Drug Administration for medical devices to ensure they are safe and effective for use.
- sensitivity and specificity
- Sensitivity refers to the ability of a test to correctly identify those with a condition, while specificity refers to the ability to correctly identify those without the condition.
- clinical study
- A clinical study is a research investigation in which people participate to evaluate the effects of a medical intervention.
Use Cases
- →Rapid cardiac diagnostics at the bedside
- →AI-guided ultrasound for clinicians without formal training
- →Treatment changes based on AI findings
- →Early patient discharge facilitated by quick diagnostics
- →Integration of AI in routine clinical workflows
- →Deployment across multiple hospital departments
Frequently Asked Questions
What is AISAP?
AISAP is an FDA-cleared AI platform designed for point of care ultrasound, enabling rapid cardiac diagnostics. It is utilized in various healthcare settings to improve patient care.
How does AISAP improve cardiac diagnostics?
AISAP enhances cardiac ultrasound examinations by allowing clinicians to perform them quickly and accurately, often in under five minutes. This rapid assessment can lead to timely treatment decisions.
What were the results of the clinical study at Sheba Medical Center?
The study found that over 30% of cases led to treatment changes, with AI-enhanced FoCUS identifying clinically relevant cardiac findings in a significant number of patients.
What is the significance of the WHO report?
The WHO report highlights real-world applications of AI in healthcare, showcasing AISAP as a leading example of how AI can transform diagnostic practices in hospitals.
What is the role of AI in POCUS?
AI plays a crucial role in POCUS by enhancing the accuracy and speed of ultrasound diagnostics, enabling clinicians to deliver specialist-level care directly at the patient's bedside.